Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative
HOUSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell
Aravive to Receive $12 Million Signing Payment , u p to an Additional $20 7 M illion in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of AVB-500 in Greater China HOUSTON and SHANGHAI, China , Nov.
Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
HOUSTON and SHANGHAI , April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced a strategic collaboration
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional investor and
HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell 2,875,000 shares of common stock at a price
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of the Society for Gynecologic Oncology 2020 Annual Meeting Recorded Webcast and Posters to be
Healthcare Entrepreneur Fred Eshelman , Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre , Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET HOUSTON , April 09, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
